<DOC>
	<DOCNO>NCT01124682</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : This phase I trial study side effect best dose 3-dimensional conformal radiation therapy treat patient bladder cancer undergone transurethral resection bladder .</brief_summary>
	<brief_title>3-Dimensional Conformal Radiation Therapy Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection Bladder</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum-tolerated dose external-beam radiotherapy deliver tumor boost patient undergone prior transurethral bladder resection muscle-invasive carcinoma bladder . Secondary - To document progression-free survival overall survival patient . - To evaluate pattern recurrence bladder preservation rate follow dose-escalated radiotherapy patient . - To determine impact acute late toxicity quality life patient . - To assess use gold seed tumor boost delineation patient . - To evaluate use virtual cystoscopy tumor localization patient . - To assess coverage phase II radiotherapy boost volume daily cone-beam image . - To assess coverage phase III radiotherapy volume cone-beam image select adaptive strategy . - To evaluate use diffusion-weighted MRI ( dwMRI ) scan assess response radiotherapy . OUTLINE : This dose-escalation study . Patients undergo rigid cystoscopy gold-seed insertion , clinically appropriate . Approximately 3-5 seed insert bladder wall demarcate maximum extent visible tumor tumor bed via customized introducer . All patient undergo 3-dimensional conformal radiotherapy daily , 5 day per week week 1 4-7 daily , 4-6 day per week week 2 3 , use combination image-guided radiotherapy technique partial bladder radiotherapy boost . Patients complete quality-of-life questionnaire QOL-30 baseline , 1 3 month , annually completion study treatment . After completion study treatment , patient follow 4 , 8 , 12 week , every 6 month 3 year , annually 2 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive bladder carcinoma , include follow cellular type : Adenocarcinoma Transitional cell carcinoma Squamous cell carcinoma Clinical stage G13 , pT2a4 disease Localized disease No bone visceral metastases No lymph node metastases Has undergone maximal transurethral resection bladder tumor plan receive radical radiotherapy PATIENT CHARACTERISTICS : WHO performance status 01 Hemoglobin &gt; 10 g/dL WBC &gt; 3,000/mm^3 Platelet count &gt; 150,000/mm^3 Creatinine &lt; 120 Î¼mol/L Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST &lt; 1.5 time ULN Alkaline phosphatase &lt; 1.5 time ULN Not pregnant No inflammatory bowel disease significant small bowel disease Physically fit radical radiotherapy No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule No malignancy within past 2 year except adequately treat basal cell carcinoma skin adequately treat carcinoma situ cervix uteri Prior superficial transitional cell carcinoma bladder allow PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior pelvic surgery No bilateral hip replacement compromise accurate radiotherapy planning No prior radiotherapy pelvis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>adenocarcinoma bladder</keyword>
	<keyword>squamous cell carcinoma bladder</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
</DOC>